Chiral inversion of drugs:: Coincidence or principle?

被引:78
作者
Wsól, V [1 ]
Skálová, L [1 ]
Szotáková, B [1 ]
机构
[1] Charles Univ Prague, Fac Pharm, Dept Biochem Sci, CZ-50005 Hradec Kralove, Czech Republic
关键词
chirality; drug metabolism; inversion; enantiomer; stereoisomer;
D O I
10.2174/1389200043335360
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
2-Arylpropionic acid derivatives are probably the most frequently cited drugs exhibiting the phenomenon that is best known as chiral inversion. One enantiomer of drug is converted into its antipode either in the presence of a solvent or more often in inner environment of an organism. Mechanistic studies of the metabolic chiral inversion were carried out for several drugs from NSAIDs, and a model of this inversion was suggested and subsequently confirmed. The chiral inversion of NSAIDs has been intensively studied in the context of the pharmacological and toxicological consequences. However, the group of NSAIDs is not the sole group of drugs in which the inversion phenomenon can be observed. There exist several other drugs that also display chiral inversion of one or even both of their enantiomers. These drugs belong to different pharmacotherapeutic groups as monoamine oxidase inhibitors, antiepileptic drugs, drugs used in the treatment of hyperlipoproteinemia or drugs that are effective in the treatment of leprosy. Moreover, some chiral or prochiral drugs are metabolized to give chiral metabolites that undergo chiral inversion too, which can have direct impact on pharmacological properties or toxicity of the drug. As the process of chiral inversion is affected by several factors, so the intensity of chiral inversion of individual substances and at different conditions can differ considerably. Interspecies differences and types of tissue are reported to be the main factors that were recognized to play the key role in the process of chiral inversion. Some of more recent studies have revealed that several other factors, such as the route of administration or interaction with other xenobiotics, can influence the enantiomeric conversion, too. Chiral inversion does not seem to be a phenomenon connected with only several drugs from some unique group of 2-arylpropionic acid derivatives: it is also observed in drugs with rather different chemical structures and is much more frequent than it can be realized.
引用
收藏
页码:517 / 533
页数:17
相关论文
共 199 条
[1]  
Aboul-Enein H.Y., 1997, IMPACT STEREOCHEMIST
[2]   HPLC on chiralcel OJ-R for enantiomer separation and analysis of ketoprofen, from horse plasma, as the 9-aminophenanthrene derivative [J].
Aboul-Enein, HY ;
van Overbeke, A ;
Vander Weken, G ;
Baeyens, W ;
Oda, H ;
Deprez, P ;
de Kruif, A .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1998, 50 (03) :291-296
[3]   PHARMACOLOGICAL DIFFERENCES BETWEEN OPTICAL ISOMERS OF IBUPROFEN - EVIDENCE FOR METABOLIC INVERSION OF (-)-ISOMER [J].
ADAMS, SS ;
BRESLOFF, P ;
MASON, CG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1976, 28 (03) :256-257
[4]   Enantiomeric HPLC separation of selected chiral drugs using native and derivatized beta-cyclodextrins as chiral mobile phase additives [J].
Ameyibor, E ;
Stewart, JT .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 1997, 20 (06) :855-869
[5]   STEREOSELECTIVE ACYL GLUCURONIDATION AND GLUCOSIDATION OF PRANOPROFEN, A 2-ARYLPROPIONIC ACID-DERIVATIVE, IN MICE INVIVO [J].
ARIMA, N .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1990, 13 (12) :733-738
[6]  
ASAMI M, 1995, BIOL PHARM BULL, V18, P1584
[7]  
ASO Y, 1990, CHEM PHARM BULL, V38, P180
[8]  
ASO Y, 1988, CHEM PHARM BULL, V36, P1834
[9]   A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model [J].
Auclair, B ;
Wainer, IW ;
Fried, K ;
Koch, P ;
Jerussi, TP ;
Ducharme, MP .
PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1228-1235
[10]   Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers [J].
Baltes, E ;
Coupez, R ;
Giezek, H ;
Voss, G ;
Meyerhoff, C ;
Benedetti, MS .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 (04) :269-277